S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
Log in

Rock Creek Pharmaceuticals Stock Price, Forecast & Analysis (OTCMKTS:RCPIQ)

$0.0006
0.00 (-25.00 %)
(As of 11/18/2019 04:00 PM ET)
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.00
Volume1,709 shs
Average Volume275,172 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta1.38
Rock Creek Pharmaceuticals, Inc., a pharmaceutical development company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its lead compound is Anatabine citrate, a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids, and non-steroidal anti-inflammatories. The company was formerly known as Star Scientific, Inc. and changed its name to Rock Creek Pharmaceuticals, Inc. in June 2014. Rock Creek Pharmaceuticals, Inc. is headquartered in Sarasota, Florida. On September 27, 2016, Rock Creek Pharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RCPIQ
Previous SymbolNASDAQ:RCPI
CUSIPN/A
Phone844-727-0727

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees5
Next Earnings DateN/A
OptionableNot Optionable

Receive RCPIQ News and Ratings via Email

Sign-up to receive the latest news and ratings for RCPIQ and its competitors with MarketBeat's FREE daily newsletter.


Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Frequently Asked Questions

What is Rock Creek Pharmaceuticals' stock symbol?

Rock Creek Pharmaceuticals trades on the OTCMKTS under the ticker symbol "RCPIQ."

Has Rock Creek Pharmaceuticals been receiving favorable news coverage?

Media headlines about RCPIQ stock have trended very negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Rock Creek Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Rock Creek Pharmaceuticals.

Who are some of Rock Creek Pharmaceuticals' key competitors?

What other stocks do shareholders of Rock Creek Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rock Creek Pharmaceuticals investors own include SLS International (SLS), Capstone Turbine (CPST), Curis (CRIS), Keryx Biopharmaceuticals (KERX), Plug Power (PLUG), xG Technology (XGTI), NovaBay Pharmaceuticals (NBY), Royal Nickel (RNX), Acer Therapeutics (ACER) and Agenus (AGEN).

Who are Rock Creek Pharmaceuticals' key executives?

Rock Creek Pharmaceuticals' management team includes the folowing people:
  • Dr. Michael John Mullan MBBS (M.D., ), Ph.D., Chairman, Chief Exec. Officer and Pres (Age 62)
  • Dr. Curtis Wright IV, Sr. VP and Medical & Clinical Director (Age 70)

How do I buy shares of Rock Creek Pharmaceuticals?

Shares of RCPIQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Rock Creek Pharmaceuticals' stock price today?

One share of RCPIQ stock can currently be purchased for approximately $0.00.

What is Rock Creek Pharmaceuticals' official website?

The official website for Rock Creek Pharmaceuticals is http://www.rockcreekpharmaceuticals.com/.

How can I contact Rock Creek Pharmaceuticals?

Rock Creek Pharmaceuticals' mailing address is 2040 WHITFIELD AVE. SUITE 300, SARASOTA FL, 34243. The company can be reached via phone at 844-727-0727 or via email at [email protected]


MarketBeat Community Rating for Rock Creek Pharmaceuticals (OTCMKTS RCPIQ)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about Rock Creek Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCPIQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCPIQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel